Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -31722.73% is 28044% below its 4-year average of -112.72%, near the low end of its 4-year range (-31722.73%–3.76%).
7574.81% below its 12-month average of -413.34%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q4 FY2025 (2025-12-31): -457.63%.
RETURN ON EQUITY (ROE)
-31722.73%
RETURN ON EQUITY (ROE) AVG TTM
-413.34%
RETURN ON EQUITY (ROE) AVG 3Y
-206.18%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-7574.81%
CURRENT VS 3Y AVG
-15285.79%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-75412.33%
vs the sector median at left
Silexion Therapeutics Ltd.
Market Cap
$109735.00
Return on Equity (ROE)
-31722.73%
TTM Avg
-413.34%
3Y Avg
-206.18%
5Y Avg
N/A
Market Cap
$95097.00
Return on Equity (ROE)
N/A
TTM Avg
-12.94%
3Y Avg
110.91%
5Y Avg
74.52%
Market Cap
$70876.00
Return on Equity (ROE)
-56.04%
TTM Avg
-428.20%
3Y Avg
-266.31%
5Y Avg
-188.29%
Market Cap
$61175.00
Return on Equity (ROE)
N/A
TTM Avg
163.76%
3Y Avg
281.78%
5Y Avg
257.03%
Market Cap
$30924.00
Return on Equity (ROE)
-33.87%
TTM Avg
-18.48%
3Y Avg
-27.44%
5Y Avg
-15.83%
Market Cap
$30263.00
Return on Equity (ROE)
-124.31%
TTM Avg
-250.62%
3Y Avg
35.28%
5Y Avg
30.27%
Market Cap
$5976.00
Return on Equity (ROE)
N/A
TTM Avg
43.59%
3Y Avg
43.03%
5Y Avg
34.44%
Market Cap
$245237.00
Return on Equity (ROE)
-287.31%
TTM Avg
-182.19%
3Y Avg
-117.96%
5Y Avg
-131.39%
Market Cap
$380715.00
Return on Equity (ROE)
-66.30%
TTM Avg
-86.35%
3Y Avg
-89.49%
5Y Avg
-12.24%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Silexion Therapeutics Ltd. (SLXN) | $109735.00 | -31722.73% | -413.34% | -206.18% | N/A |
| Psyence Biomedical Ltd. (PBM)vs › | $95097.00 | N/A | -12.94% | 110.91% | 74.52% |
| PRF Technologies Ltd. (PRFX)vs › | $70876.00 | -56.04% | -428.20% | -266.31% | -188.29% |
| Akanda Corp. (AKAN)vs › | $61175.00 | N/A | 163.76% | 281.78% | 257.03% |
| Zhongchao Inc. (ZCMD)vs › | $30924.00 | -33.87% | -18.48% | -27.44% | -15.83% |
| Mobile-health Network Solutions Class A Ordinary Shares (MNDR)vs › | $30263.00 | -124.31% | -250.62% | 35.28% | 30.27% |
| NewGenIvf Group Limited (NIVF)vs › | $5976.00 | N/A | 43.59% | 43.03% | 34.44% |
| SciSparc Ltd. (SPRC)vs › | $245237.00 | -287.31% | -182.19% | -117.96% | -131.39% |
| Virax Biolabs Group Limited (VRAX)vs › | $380715.00 | -66.30% | -86.35% | -89.49% | -12.24% |
| Niki BioSolutions, Inc. (NIKI)vs › | $381940.00 | -5.89% | -13.04% | -24.95% | -31.50% |
ROE
-31722.7%
ROA
-328.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | -457.63% |
| 2025-09-30 | -132.54% |
| 2025-03-31 | -649.85% |
| 2023-09-30 | -4.16% |
| 2023-06-30 | 3.76% |
| 2023-03-31 | 3.31% |
| 2022-09-30 | -0.13% |
| 2022-06-30 | -0.58% |
| 2022-03-31 | -0.79% |
| 2021-12-31 | -0.66% |
| 2021-09-30 | -0.62% |
